We are watching CHM.AX stock after a 100.00% pre-market gain on the ASX to A$0.002. The jump follows thin-volume trading with 4,612,525 shares changing hands versus an average of 4,757,511. Chimeric Therapeutics Limited (ASX: CHM.AX) is a clinical-stage biotechnology name with active CAR-T and NK programs. We summarise drivers, valuation metrics, technical cues and a model-based price outlook to help investors weigh upside and risk in the Australian healthcare sector.
CHM.AX stock pre-market move and immediate drivers
CHM.AX stock moved from a previous close of A$0.001 to an open of A$0.002, a 100.00% one-day change. Volume was 4,612,525, near average daily flow of 4,757,511, so liquidity lifted but remains modest. The ASX-listed move appears tied to renewed interest in clinical readouts and small-block trading rather than a public announcement. Watch for formal company updates or placement notices that would validate sustained price momentum.
Clinical pipeline catalysts behind CHM.AX stock momentum
Chimeric Therapeutics (CHM.AX) runs multiple early-stage programs including CHM 0201 (NK platform) and CHM 1101 (CLTX CAR-T) in phase I trials for solid tumours and glioblastoma. Clinical progress or interim safety signals are typical near-term catalysts for biotech microcaps. Investors should follow the company website and trial registries for protocol dates and investigator updates source. Positive early data would be a clear catalyst for further upside.
Valuation and financial metrics for CHM.AX stock
At A$0.002, market capitalisation is roughly A$8,837,407 with 4,418,703,619 shares outstanding. Trailing EPS is -0.01 and reported PE is -0.20, reflecting losses. Key ratios: price-to-sales 1.2394, price-to-book -1.0757, and current ratio 0.6941. Cash per share is 0.000768. These figures highlight a capital‑consuming clinical franchise and potential dilution risk if fundraising occurs.
Technical snapshot and trading metrics for CHM.AX stock
Technical indicators show short-term weakness but rising trend strength. RSI is 34.31 and ADX reads 39.05, signalling a strong trend forming. Price averages: 50‑day A$0.0021, 200‑day A$0.00309. Year range is A$0.001–A$0.009. Watch order book depth; OBV stands at 21,986,135 but bid liquidity can evaporate quickly at microcap levels.
Meyka AI grade and model forecast for CHM.AX stock
Meyka AI rates CHM.AX with a score of 69.72/100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12‑month base-case price of A$0.006, an implied upside of 200.00% from the current A$0.002. Forecasts are model-based projections and not guarantees. Investors should treat the projection as one scenario among many and expect high volatility.
Risks and practical considerations for CHM.AX stock investors
Primary risks: clinical trial failure, fundraising dilution, and low liquidity. Financials show negative operating cash flow per share -0.0018887 and limited working capital. Sector risks include competitive biotech development and regulatory hurdles in healthcare. For trading, set tight stops and monitor company announcements. For research, use official filings and reliable market pages such as Meyka AI’s stock page for CHM.AX source.
Final Thoughts
CHM.AX stock is a top gainer in pre‑market trade after a 100.00% move to A$0.002, driven by thin liquidity and renewed attention to its CAR‑T and NK clinical programs. The company’s fundamentals show a loss‑making, development‑stage biotech with a market cap of roughly A$8.84 million, negative EPS and a current ratio 0.6941 that points to funding needs. Technically, an ADX of 39.05 suggests a strong trend, but RSI 34.31 signals near‑term oversold conditions. Meyka AI’s model projects a 12‑month base‑case of A$0.006 (implied +200.00%), though forecasts are not guarantees. In our view, CHM.AX suits speculative biotech investors who can accept high volatility and dilution risk. Monitor clinical readouts, corporate announcements and any capital raises, and treat positions as high-risk, event-driven trades rather than core holdings. Meyka AI provides this AI-powered market analysis platform data to help orient that assessment.
FAQs
What caused the CHM.AX stock surge pre-market?
The pre-market surge reflected a price move from A$0.001 to A$0.002 on thin but active volume. No confirmed announcement was posted. Such moves in microcap biotech often stem from clinical speculation or block trades, not established company news.
What are the main valuation metrics for CHM.AX stock?
Key metrics: market cap A$8,837,407, EPS -0.01, PE -0.20, price-to-sales 1.2394, current ratio 0.6941. These signal a development-stage biotech with negative earnings and potential need for funding.
What is Meyka AI’s forecast for CHM.AX stock?
Meyka AI’s forecast model projects a 12‑month base-case of A$0.006, an implied upside of 200.00% versus A$0.002. This is a model projection and not a guarantee; outcomes depend on clinical and financing events.
Is CHM.AX stock suitable for long-term investors?
CHM.AX is speculative for long-term investors. It has an active clinical pipeline but negative cash flow and dilution risk. Long-term holders should monitor trials, cash runway and regulatory updates before increasing exposure.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)